Advertisement

The Role of Tumor Infiltrating Lymphocyte (TIL) Therapy in NSCLC

An expert in thoracic oncology, Adam J. Schoenfeld, MD, provides key insight into the use of cell therapy in non-small cell lung cancer after first-line treatment and highlights the potential for tumor-infiltrating lymphocyte (TIL) therapy depending on results from ongoing clinical trials.

EP. 1: Treatment Options in NSCLC After First-Line Therapy

May 11th 2021

Adam J. Schoenfeld, MD, provides key insights into treatment options for patients with non–small cell lung cancer whose tumors progress after first-line therapy.

EP. 2: Cell Therapies for Patients With NSCLC

May 11th 2021

A key opinion leader in thoracic oncology discusses factors to consider regarding emerging cell therapy options in non–small cell lung cancer, such as CAR T, TCR, and TIL therapies.

EP. 3: An Overview of TIL Therapy

May 11th 2021

An expert in the management of non–small cell lung cancer defines tumor-infiltrating lymphocyte (TIL) therapy by discussing its mechanism of action and reviewing its impact in other disease states, such as myeloma.

EP. 4: The Potential Role of TIL Therapy in NSCLC

May 11th 2021

Adam J. Schoenfeld, MD, considers the benefits and limitations of tumor-infiltrating lymphocyte (TIL) therapy and discusses its potential impact on the treatment landscape in non–small cell lung cancer.

EP. 5: Clinical Trials of TIL Therapy in NSCLC

May 18th 2021

A key opinion leader in the management of lung cancer offers insight into ongoing clinical trials of tumor-infiltrating lymphocyte (TIL) therapy in non–small cell lung cancer.

EP. 6: Treatment Considerations for TIL Therapy in NSCLC

May 18th 2021

An expert thoracic oncologist, Adam J. Schoenfeld, MD, highlights key factors that patients and providers should take into account when considering cell therapy in non–small cell lung cancer.

Advertisement
Advertisement